Navigation Links
Relief for HIV/AIDS patients: ART therapy now available in India

While experts have reacted with skepticism to a British man's claims that he has been cured of HIV/AIDS, patients from India are in for some relief. //

In what is assumed as a social relief for HIV/AIDS patients, Anti-Retro Virus Treatment (ART) drugs are now available in India.

This medicine is provided in India by National AIDS Control Organization (NACO) and it is hoped that it would help the infected people to lead a much longer life.

Dr Moji Jini, a surgical specialist of Arunachal General Hospital, Itanagar who underwent a four-day training programme on ART therapy at Regional Institute of Medical Sciences (RIMS) recently, said the therapy would control infection, kill the virus and increase the immunity system.

''There is tremendous stigma attached to this disease. People should seek counseling and avail ART therapy. This medicine would ensure a stress-free life,'' he observed.

The disease generally reduces the life span of the patients. With this medicine their life span would increase by five to ten years.

But the patient should adopt safer behaviour and remain on regular medication. It would cost Rs 1500 per month or even lesser (around Rs 600) if subsidized by the government, he said.

To improve health and education, the leaders world over have agreed to work to make HIV/AIDS anti-retrovirus treatment available to all who need it, and to make available objective assessments of the effectiveness of school systems.
'"/>




Page: 1

Related medicine news :

1. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
2. Relief from common back pain
3. Relief to pregnant women using fertility drugs
4. Relief of pain for suffering patients
5. Relief from cancer pain with anticonvulsants
6. Relief from Migraine
7. Pain Relief For Osteoarthritis Patients
8. Relief From Migraines
9. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
10. Drug Found To Bring Relief For Individuals With Early Parkinson’
11. Relief For Women Suffering From Fibromyalgia
Post Your Comments:
(Date:12/7/2009)... Results of two new studies support the use ... (AED) Vimpat® for patients requiring add-on therapy in ... not feasible. These data, which were presented ... the American Epilepsy Society in Boston, further clarify ... setting. ,, One study shows that patients can ...
(Date:12/7/2009)... -- Micromet, Inc. (Nasdaq: MITI ), a ... treatment of cancer, inflammation and autoimmune diseases, today ... data from its ongoing phase 1 clinical trial ... non-Hodgkin,s lymphoma (NHL) at the 51ST Annual Meeting ... New Orleans, Louisiana. Blinatumomab is a CD19-specific, T ...
(Date:12/7/2009)... couple years ago, lead paint in toys manufactured ... made in the USA. This fall, news of ... toys are suspect. Renowned parenting expert Dr. Jeffrey ... harmful to developing brains, retarding language development and ... sense of separation, which is the defining trait ...
(Date:12/7/2009)... Barduson was recently named executive chairman of the board of ... physicians in hospitals and practices nationwide. , ... ... Gene Barduson was recently named executive chairman of the ... company currently serving 13,000 physicians in hospitals and practices nationwide. ...
(Date:12/7/2009)... PALM BEACH, Fla., Dec. 7 The ... TransMedia Group to publicize the first major ... the Simply 66 Snap System, which is already ... TransMedia Group ( www.transmediagroup.com ) was selected as ... profile in print, broadcast, online and social networking ...
Breaking Medicine News(10 mins):Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 4Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 5Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4Health News:Top 10 Toys That Will Scar Your Child for Life 2Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Cubicle Curtain Factory Retains TransMedia Group to Promote First Privacy Curtain to Reduce Hospital Maintenance Cost 2
... indoor plumbing to be the pinnacle of sanitary ... better solution for many parts of the developing ... Associate Professor David Watkins, Professor James Mihelcic and ... Futures Institute analyzed worldwide barriers to sanitation. Diseases ...
... the hormone could boost death risk, researchers say , , ... levels put men at high risk for cardiovascular disease, ... help better the odds, according to new studies. ... become more common with age, are linked to several ...
... in the strength of cannabis over the last decade is ... users are not borne out by a study of the ... Research Centre (NDARC) and the National Drug Research Institute (NDRI), ... this month,s issue of ADDICTION, are that increased potency has ...
... Health Care & Economic Security - Need,for Lawmakers to ... 17 150 years ago,this week, Abraham Lincoln delivered ... Springfield. AARP Illinois took the opportunity,to remind state and ... of division preventing progress on key issues remains the,same., ...
... creators of the leading exergaming ,Brand Xperience, ... the exergaming market in ... iTech Fitness Inc.,( http://www.iTechFitness.com ), creators of the ... signing of the 50th XRKade,location in North America with ...
... Associates, leading analysts will,explore the implications of high-speed ... homes as a kickoff to CONNECTIONS(TM): The,Digital Living ... Top Trends to Watch, Tuesday, June 24,will feature ... on trends in,broadband and access services, video delivery, ...
Other Medicine News:Health News:Studies Support Testosterone Supplements for Older Men 2Health News:Claims linking health problems and the strength of cannabis may be exaggerated 2Health News:150 Years Later 'House Divided' Speech Still Holds Strong Message 2Health News:XRKade Signs 50th Location in North America and Announces Expansion Plans 2Health News:Parks Associates Analysts Present Insights on Broadband, Digital Content, Advertising, Home Systems, and Digital Health at CONNECTIONS(TM) 2
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, announced today the presentation of new data from ... recombinant Protective Antigen (rPA) based anthrax vaccine is structurally ... up to and including 55 degrees C. The ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
(Date:12/4/2009)... Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New ... Administration seeking approval to market its 8mg ramelteon tablets ... Takeda Pharmaceutical Company Limited. Watson,s 8mg ramelteon tablet ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Web Based Psychotherapy Can Work 55000 1Web Based Psychotherapy Can Work 55000 2Web Based Psychotherapy Can Work 55000 3Learning how to cope with burn injuries 54996 1Learning how to cope with burn injuries 54996 2Learning how to cope with burn injuries 54996 3Missouri Botanical Garden hosts historic meeting to discuss endangered plants in the Caucasus region 9646 1Missouri Botanical Garden hosts historic meeting to discuss endangered plants in the Caucasus region 9646 2
... ANTIPOLIS, France, Oct. 2 NicOx S.A.,(Eurolist: ... clinical and,preclinical results from its collaboration with ... of Dermatology, in Buenos Aires, Argentina.,These included ... prototype compound, showing,the potential for improved safety ...
... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) today announced that ... overview of the Company,s cancer,pipeline at the upcoming William ... City. Dr. Henderson,s presentation will take place,on Wednesday, October ... will be webcast live and will be,accessible from the ...
Other Medicine Technology:NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 2NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 3Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference 2